U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Physostigmine. [Updated 2018 Dec 3].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Physostigmine

Revised: December 3, 2018.

CASRN: 57-47-6



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of physostigmine during breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information in nursing mothers was not found as of the revision date. In animals, cholinergic drugs increase oxytocin release,[2] and have variable effects on serum prolactin.[3] Physostigmine increases serum prolactin in humans.[4][5] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1. Clarke G, Fall CH, Lincoln DW, Merrick LP. Effects of cholinoceptor antagonists on the suckling-induced and experimentally evoked release of oxytocin. Br J Pharmacol. 1978;63:519-27. PubMed PMID: 566601.
2. Muller EE, Locatelli V, Cella S et al. Prolactin-lowering and -releasing drugs: mechanisms of action and therapeutic applications. Drugs. 1983;25:399-432. PubMed PMID: 6133737.
3. Risch SC, Janowsky DS, Siever LJ al. Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans. Peptides. 1982;3:319-22. PubMed PMID: 6289276.
4. Risch SC, Janowsky DS, Siever LJ et al. Cholinomimetic-induced co-release of prolactin and beta-endorphin in man. Psychopharmacol Bull. 1982;18:21-5. PubMed PMID: 6296908.

Substance Identification

Substance Name

Physostigmine

CAS Registry Number

57-47-6

Drug Class

Breast Feeding

Lactation

Cholinesterase Inhibitors

Parasympathomimetics